HALOZYME THERAPEUTICS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-12-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-06-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-03-31 was -$126.00K.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2023 was -$126.00K, a 107.44% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $1.69M, a 87.08% decline from fiscal 2021.
- HALOZYME THERAPEUTICS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $13.10M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$126.00K 10-K · filed 2026-02-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$126.00K derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.57M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$126.00K 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $1.69M 10-K · filed 2025-02-18 |
| 2022-09-30 | $1.69M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $13.10M 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | |
| 2021-03-31 | $13.10M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |